-
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren’s disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience data to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more… Source: Read More
-
A Medical Milestone: FDA Approves First-Ever Treatment for Warm Autoimmune Hemolytic Anemia
NYSE: $JNJ A Breakthrough for Patients In a significant milestone for hematology and immunology, the FDA has officially approved Imaavy (nipocalimab-aahu). This approval marks a historical turning point as it is the first-ever treatment specifically indicated for adults with warm autoimmune hemolytic anemia (wAIHA). Understanding Warm Autoimmune Hemolytic Anemia (wAIHA) Warm autoimmune hemolytic anemia is…